Mizuho Securities analyst Uy Ear maintains $Alkermes (ALKS.US)$ with a buy rating, and sets the target price at $40.
According to TipRanks data, the analyst has a success rate of 41.9% and a total average return of 3.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
The adjustment in valuation multiple for Alkermes, influenced by the recent trend among biotech peers, is the basis for the revised outlook. The upcoming expert discussion on sleep disorders, particularly anticipating orexin data in 2025, will concentrate on the projected updates from Alkermes and Centessa's Phase 2 narcolepsy data.
The firm adjusted its forecast following a sum-of-the-parts analysis. The discussion among investors is increasingly focusing on ALKS 2680, anticipating more spotlight as it heads towards Phase 2 outcomes in the latter half of 2025. Its potential impact on the $10B branded narcolepsy and idiopathic hypersomnia markets is being closely watched.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞穗證券分析師Uy Ear維持$阿爾凱默斯 (ALKS.US)$買入評級，目標價40美元。
根據TipRanks數據顯示，該分析師近一年總勝率為41.9%，總平均回報率為3.3%。
此外，綜合報道，$阿爾凱默斯 (ALKS.US)$近期主要分析師觀點如下：
受生物技術同行最近趨勢的影響，Alkermes估值倍數的調整是修訂前景的基礎。即將舉行的關於睡眠障礙的專家討論，特別是對2025年食慾素數據的預測，將集中在Alkermes和Centessa的第二階段發作性睡病數據的預計更新上。
該公司在進行各部分總和分析後調整了預測。投資者之間的討論越來越多地集中在ALKS 2680上，預計隨着ALKS 2680在2025年下半年邁向第二階段的結果，他們將受到更多關注。它對價值100億美元的品牌發作性睡病和特發性睡眠過度市場的潛在影響正在受到密切關注。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
